Compare
Establishment Labs Holdings Inc. vs Inogen Inc vs Sanara MedTech Inc. vs Cadre Holdings, Inc.
| Latest fiscal year | Establishment Labs Holdings Inc. ESTA | Inogen Inc INGN | Sanara MedTech Inc. SMTI | Cadre Holdings, Inc. CDRE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $211.08M | $348.67M | $103.12M | $610.31M |
| Revenue growth (YoY) | +27.1% | +3.9% | +19.0% | +7.5% |
| Gross margin | 69.3% | 44.2% | 92.7% | 42.5% |
| Operating margin | -18.5% | -8.7% | 7.1% | 11.0% |
| Net margin | -24.2% | -6.5% | -36.4% | 7.2% |
| Net income | -$51.06M | -$22.75M | -$37.56M | $44.14M |
| EPS (Diluted) | -$1.72 | -$0.86 | -$4.36 | $1.02 |
| Operating cash flow | -$50.89M | -$11.22M | $6.79M | $63.70M |
| Free cash flow | -$56.94M | -$13.74M | $2.16M | $56.85M |
| Cash & equivalents | $75.57M | $103.73M | $16.58M | $122.90M |
| Total assets | $357.17M | $298.62M | $72.94M | $770.03M |
| Total liabilities | $333.62M | $106.39M | $67.01M | $452.23M |
| Shareholders' equity | $23.55M | $192.23M | $5.94M | $317.80M |
| Return on year-end equity | -216.9% | -11.8% | -632.5% | 13.9% |
| Shares outstanding | 29.30M | 27.23M | 8.95M | 42.16M |
Revenue, most recent five fiscal years
| Fiscal year | Establishment Labs Holdings Inc. | Inogen Inc | Sanara MedTech Inc. | Cadre Holdings, Inc. |
|---|---|---|---|---|
| Latest | $211.08M Ended 2025-12-31 | $348.67M Ended 2025-12-31 | $103.12M Ended 2025-12-31 | $610.31M Ended 2025-12-31 |
| 1 year earlier | $166.03M Ended 2024-12-31 | $335.70M Ended 2024-12-31 | $86.67M Ended 2024-12-31 | $567.56M Ended 2024-12-31 |
| 2 years earlier | $165.15M Ended 2023-12-31 | $315.66M Ended 2023-12-31 | $64.99M Ended 2023-12-31 | $482.53M Ended 2023-12-31 |
| 3 years earlier | $161.70M Ended 2022-12-31 | $377.24M Ended 2022-12-31 | $45.84M Ended 2022-12-31 | $457.84M Ended 2022-12-31 |
| 4 years earlier | $126.68M Ended 2021-12-31 | $358.00M Ended 2021-12-31 | $24.14M Ended 2021-12-31 | $427.29M Ended 2021-12-31 |